Literature DB >> 12440182

Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience.

Eva Kline-Rogers1, David Share, Diane Bondie, Bruce Rogers, Dean Karavite, Sherri Kanten, Patricia Wren, Cindy Bodurka, Cathy Fisk, John McGinnity, Susan Wright, Susan Fox, Kim A Eagle, Mauro Moscucci.   

Abstract

The technical challenges in the development of a quality-controlled registry of percutaneous coronary interventions (PCIs) are currently unknown. This article describes the authors' experience in the development of a regional, quality-controlled PCI registry. In 1996, 16 centers in Michigan were invited to participate in a multicenter PCI registry. Nine centers agreed to a pilot data collection and, as of July 2001, eight centers are still actively collecting data. An Oracle database was developed by the coordinating center. A common data collection form and a standard set of definitions were agreed on during several meetings. Data validity was insured through review of each form by a trained nurse, by automatic database diagnostic routines, and by site visits that included a review of the catheterization laboratory logs and a review of randomly selected charts. The average number of forms requiring query resolution was 33% in 1997 (range 7-76%), and it decreased to 5% in 1999 (range 1.4-10%). The most commonly queried variables were outcomes prior to discharge, lesion category, lesion complexity, date of birth, device used, gender, postprocedural percent stenosis, presence of left main disease, and MI date. Invalid dates, identification of the doctor, the presence of duplicate forms, and of duplicate outcomes were additional common queries generated by the internal diagnostic routines. In conclusion, the number of queries and diagnostic reports generated in the database suggests that the development of a quality-controlled PCI registry requires the institution of a careful diagnostic and data quality assessment system.

Mesh:

Year:  2002        PMID: 12440182     DOI: 10.1111/j.1540-8183.2002.tb01072.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  17 in total

1.  The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.

Authors:  Emily Perdoncin; Milan Seth; Simon Dixon; Louis Cannon; Akshay Khandelwal; Arthur Riba; Shukri David; David Wohns; Hitinder Gurm
Journal:  Eur Heart J       Date:  2015-09-15       Impact factor: 29.983

2.  Exploring the Healthcare Value of Percutaneous Coronary Intervention: Appropriateness, Outcomes, and Costs in Michigan Hospitals.

Authors:  Daniel M Alyesh; Milan Seth; David C Miller; James M Dupree; John Syrjamaki; Devraj Sukul; Simon Dixon; Eve A Kerr; Hitinder S Gurm; Brahmajee K Nallamothu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-06

3.  Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).

Authors:  Devraj Sukul; Milan Seth; Simon R Dixon; Akshay Khandelwal; Thomas A LaLonde; Hitinder S Gurm
Journal:  J Invasive Cardiol       Date:  2017-04-15       Impact factor: 2.022

4.  Predicting complications of percutaneous coronary intervention using a novel support vector method.

Authors:  Gyemin Lee; Hitinder S Gurm; Zeeshan Syed
Journal:  J Am Med Inform Assoc       Date:  2013-04-18       Impact factor: 4.497

5.  The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).

Authors:  Devraj Sukul; Milan Seth; Theodore Schreiber; George Hanzel; Akshay Khandelwal; Louis A Cannon; Thomas A Lalonde; Hitinder S Gurm
Journal:  J Interv Cardiol       Date:  2017-05-22       Impact factor: 2.279

6.  The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.

Authors:  Devraj Sukul; Milan Seth; Theodore Schreiber; Akshay Khandelwal; Louis A Cannon; Thomas A LaLonde; Hitinder S Gurm
Journal:  Catheter Cardiovasc Interv       Date:  2017-03-17       Impact factor: 2.692

7.  Drivers of Variation in 90-Day Episode Payments After Percutaneous Coronary Intervention.

Authors:  Devraj Sukul; Milan Seth; James M Dupree; John D Syrjamaki; Andrew M Ryan; Brahmajee K Nallamothu; Hitinder S Gurm
Journal:  Circ Cardiovasc Interv       Date:  2019-01       Impact factor: 6.546

8.  Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan.

Authors:  Thomas F Boyden; Karen E Joynt; Lisa McCoy; Megan L Neely; Matthew A Cavender; Simon Dixon; Frederick A Masoudi; Eric Peterson; Sunil V Rao; Hitinder S Gurm
Journal:  Am Heart J       Date:  2015-09-16       Impact factor: 4.749

9.  Outcomes After Percutaneous Coronary Intervention in Patients With a History of Cerebrovascular Disease: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.

Authors:  Chris Song; Devraj Sukul; Milan Seth; David Wohns; Simon R Dixon; Nicklaus K Slocum; Hitinder S Gurm
Journal:  Circ Cardiovasc Interv       Date:  2018-06       Impact factor: 6.546

10.  Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium).

Authors:  Chris Song; Devraj Sukul; Milan Seth; James M Dupree; Akshay Khandelwal; Simon R Dixon; David Wohns; Thomas LaLonde; Hitinder S Gurm
Journal:  Am J Cardiol       Date:  2017-08-30       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.